OptiBiotix Health Regulatory News (OPTI)

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Distribution agreement with Actial Farmaceutica Srl

Agreement signed with ProBiotix Health Ltd for CholBiome® and CholBiome®X3

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that its wholly-owned subsidiary, ProBiotix Health Ltd ("ProBiotix"), has entered into a non-exclusive distribution agreement with Actial Farmaceutica Srl ("Actial") for the distribution of CholBiome® and CholBiome®X3 in four new territories in the Asia Pacific region.

Actial is an Italian holding company with three subsidiaries worldwide: CD Pharma India, Actial APAC and VSL Pharmaceuticals focused on the development of probiotic bacteria to improve gut health. Actial is the developer and originator of one of the world's best known probiotic brand called VSL#3®. 

The agreement grants Actial the right to distribute ProBiotix's cholesterol and blood pressure reducing dietary supplements, CholBiome® and CholBiome®X3 in Australia, New Zealand, Indonesia and Thailand. CholBiome® and CholBiome®X3 will be marketed under the VSL#3® range to hospital clinicians, GPs and pharmacies as probiotic dietary food supplements for the management of high cholesterol and blood pressure. The agreement extends ProBiotix' commercial reach of its finished dietary products containing its cholesterol reducing LP LDL® strain into new territories as a product line extension of the VSL#3® brand.

ProBiotix was created to develop science based healthy lactic acid bacteria called probiotics to reduce cardiovascular risk. Independent clinical studies have shown its LP LDL® probiotic can reduce key cardiovascular biomarkers such as total cholesterol, LDL (bad) cholesterol, and blood pressure by up to 36.7%, 13.9% and 5.1% respectively. Since launching its CholBiome® products containing LP LDL® in May 2017, ProBiotix has signed approximately 30 agreements with products commercialised in 50 countries.

Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health Ltd: "We are pleased to announce the signing of this distribution agreement with Actial Farmaceutica Srl as we believe cholesterol reducing probiotics like LPLDL® are increasingly being seen by clinicians and health care professionals as a naturally safe and effective approach to reducing cardiovascular risk. We chose Actial due to a common interest in developing probiotics with strong science and clinical studies and their expertise in commercialising value added probiotics to major global pharmaceutical markets.

"We believe working with Actial, and similar partners around the world, provides the best opportunity to expand the range of applications for LP LDL® and CholBiome® to a wide range of industry sectors. This agreement is another step in our low cost approach to growing revenues by building manufacturing, formulation/application and distribution partnerships which provide revenues across the whole value chain in multiple industry sectors."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.